
## Jiaxin Zhou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3192170/publications.pdf Version: 2024-02-01



Ιμαχίνι Ζησιι

#	Article	IF	CITATIONS
1	The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease. Rheumatology, 2022, 61, 815-825.	1.9	5
2	Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis. Clinical Infectious Diseases, 2022, 74, 734-742.	5.8	88
3	Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4–related disease. Rheumatology, 2022, 61, 2197-2209.	1.9	3
4	SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study. Rheumatology, 2022, 61, 1841-1848.	1.9	3
5	Persistent enlargement of the pancreatic gland after glucocorticoid therapy increases the risk of relapse in IgG4-related autoimmune pancreatitis. Clinical Rheumatology, 2022, , 1.	2.2	2
6	Prediction of new organ onset in recurrent immunoglobulin G4–related disease during 10Âyears of followâ€up. Journal of Internal Medicine, 2022, 292, 91-102.	6.0	3
7	Secukinumab in the treatment of parenchymal neuro-Behçet's syndrome. Rheumatology, 2022, 61, e277-e279.	1.9	2
8	Case Fatality Risk of the First Pandemic Wave of Coronavirus Disease 2019 (COVID-19) in China. Clinical Infectious Diseases, 2021, 73, e79-e85.	5.8	50
9	Differences in clinical characteristics of IgC4-related disease across age groups: a prospective study of 737 patients. Rheumatology, 2021, 60, 2635-2646.	1.9	16
10	Rheumatic immuneâ€related adverse events induced by immune checkpoint inhibitors. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 178-185.	1.1	17
11	Risk and prognosis factors for systemic sclerosis with lung cancer: A singleâ€centre caseâ€control study in China. International Journal of Clinical Practice, 2021, 75, e13819.	1.7	1
12	The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother–neonate cohort study. Lancet Infectious Diseases, The, 2021, 21, 418-426.	9.1	14
13	Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. Rheumatology, 2021, 60, 2472-2477.	1.9	20
14	MicroRNA-320a: an important regulator in the fibrotic process in interstitial lung disease of systemic sclerosis. Arthritis Research and Therapy, 2021, 23, 21.	3.5	14
15	Renal Involvement and HBV Infection Are Common in Chinese Patients With Cryoglobulinemia. Frontiers in Immunology, 2021, 12, 580271.	4.8	3
16	Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China. Orphanet Journal of Rare Diseases, 2021, 16, 152.	2.7	8
17	Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study. Arthritis Research and Therapy, 2021, 23, 102.	3.5	10
18	Kinetics of the neutralising antibody response in patients with hand, foot, and mouth disease caused by EV-A71: A longitudinal cohort study in Zhengzhou during 2017-2019. EBioMedicine, 2021, 68, 103398.	6.1	8

JIAXIN ZHOU

#	Article	IF	CITATIONS
19	Characteristics and Outcomes of Coronary Artery Involvement in Polyarteritis Nodosa. Canadian Journal of Cardiology, 2021, 37, 895-903.	1.7	8
20	Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China. Clinical Rheumatology, 2021, 40, 4589-4596.	2.2	4
21	Proteomic analyses of plasma-derived exosomes in immunoglobulin (Ig) G4-related disease and their potential roles in B cell differentiation and tissue damage. Journal of Autoimmunity, 2021, 122, 102650.	6.5	6
22	Comparison of pathological findings between patients with relapsed and non-relapsed immunoglobin G4-related disease. Chinese Medical Journal, 2021, Publish Ahead of Print, .	2.3	0
23	Peripheral B-Cell Immunophenotyping Identifies Heterogeneity in IgG4-Related Disease. Frontiers in Immunology, 2021, 12, 747076.	4.8	7
24	Comparison of relapsing polychondritis patients with and without central nervous system involvement: A retrospective study of 181 patients. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110005.	2.1	9
25	UPLC-MS based plasma metabolomics and lipidomics reveal alterations associated with IgG4-related disease. Rheumatology, 2021, 60, 3252-3261.	1.9	4
26	Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China. Emerging Microbes and Infections, 2021, 10, 2303-2312.	6.5	10
27	Long-Term Outcomes of IgG4-Related Ophthalmic Disease in a Chinese IgG4-Related Disease Cohort. Frontiers in Medicine, 2021, 8, 784520.	2.6	5
28	Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients. BMC Ophthalmology, 2021, 21, 447.	1.4	3
29	Management of immune checkpoint inhibitorâ€related dermatologic adverse events. Thoracic Cancer, 2020, 11, 488-492.	1.9	17
30	Management of immune checkpoint inhibitorâ€related rheumatic adverse events. Thoracic Cancer, 2020, 11, 198-202.	1.9	2
31	Clinical diagnosis and treatment of immune checkpoint inhibitorâ€associated pneumonitis. Thoracic Cancer, 2020, 11, 191-197.	1.9	52
32	Clinical manifestation and management of immune checkpoint inhibitorâ€associated cardiotoxicity. Thoracic Cancer, 2020, 11, 475-480.	1.9	9
33	Use of glucocorticoids in the management of immunotherapyâ€related adverse effects. Thoracic Cancer, 2020, 11, 3047-3052.	1.9	13
34	Clinical features and longâ€ŧerm outcomes of Chinese patients with scleroderma renal crisis. International Journal of Rheumatic Diseases, 2020, 23, 1194-1200.	1.9	3
35	Serum IgE in the clinical features and disease outcomes of IgC4-related disease: a large retrospective cohort study. Arthritis Research and Therapy, 2020, 22, 255.	3.5	18
36	Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Study in the Chinese Population. Frontiers in Medicine, 2020, 7, 583944.	2.6	12

JIAXIN ZHOU

#	Article	IF	CITATIONS
37	Clinical manifestations of Behçet's disease in a large cohort of Chinese patients: gender- and age-related differences. Clinical Rheumatology, 2020, 39, 3449-3454.	2.2	8
38	Clinical diagnosis and treatment of immune checkpoint inhibitorâ€associated adverse events in the digestive system. Thoracic Cancer, 2020, 11, 829-834.	1.9	5
39	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitorâ€related hematological adverse events. Thoracic Cancer, 2020, 11, 799-804.	1.9	24
40	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thoracic Cancer, 2020, 11, 810-818.	1.9	19
41	Clinical diagnosis and treatment of immune checkpoint inhibitorsâ€related endocrine dysfunction. Thoracic Cancer, 2020, 11, 1099-1104.	1.9	5
42	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. Thoracic Cancer, 2020, 11, 805-809.	1.9	8
43	Management of immune checkpoint inhibitorâ€related adverse events: A review of case reports. Thoracic Cancer, 2020, 11, 498-504.	1.9	10
44	Specificity, kinetics and longevity of antibody responses to avian influenza A(H7N9) virus infection in humans. Journal of Infection, 2020, 80, 310-319.	3.3	9
45	Systemic lupus erythematosus gastrointestinal involvement: a computed tomography-based assessment. Scientific Reports, 2020, 10, 6400.	3.3	6
46	Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4â€related diseases: A prospective clinical trial. International Journal of Rheumatic Diseases, 2019, 22, 1479-1488.	1.9	17
47	The Clinical Features and Risk Factors of Parenchymal Neuro-Behcet's Disease. Journal of Immunology Research, 2019, 2019, 1-7.	2.2	8
48	Effectiveness and safety of interferon α2a as an add-on treatment for refractory Behçet's uveitis. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231984788.	2.5	12
49	Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy. Arthritis Research and Therapy, 2019, 21, 44.	3.5	18
50	The Clinical Features, Risk Factors, and Outcome of Aneurysmal Lesions in Behcet's Disease. Journal of Immunology Research, 2019, 2019, 1-8.	2.2	14
51	Tocilizumab in the treatment of severe and/or refractory vasculo-Behçet's disease: a single-centre experience in China. Rheumatology, 2018, 57, 2057-2059.	1.9	13
52	The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 171-175.	0.8	13
53	Clinical characteristics of immunoglobulin G4–related disease: a prospective study of 118 Chinese patients. Rheumatology, 2015, 54, 1982-1990.	1.9	185
54	The clinical features, image findings and risk factors of vena cava syndrome in Behçet's syndrome. Clinical and Experimental Rheumatology, 0, , .	0.8	2